Endometrial Stromal Tumors

These are tumors that form in the connective tissue (stroma) of the uterine lining. Sometimes they can grow into the muscle wall of the uterus. They are classified based on how abnormal the cells look.

Condition

What people with Endometrial Stromal Tumors report

Every report comes from a Lived member, sent anonymously.

Have you had Hysterectomy for Endometrial Stromal Tumors?

NameHow it went

About Endometrial Stromal Tumors

What It Is

Endometrial stromal tumors are rare growths that start in the stroma of the uterus, the supporting tissue beneath the uterine lining (the endometrium). They usually grow into the muscular wall of the uterus. The most common symptoms are abnormal vaginal bleeding, heavy periods, pelvic pain or pressure, and an enlarged uterus or a mass that can be felt in the pelvis. Some are found by chance during an exam or during surgery for something else. The name covers several tumors that behave very differently. An endometrial stromal nodule is benign, meaning it is not cancer. Low-grade endometrial stromal sarcoma is a slow-growing cancer that is usually found early and often responds to hormone treatment. High-grade endometrial stromal sarcoma grows faster and is more often found after it has spread. A related tumor, undifferentiated uterine sarcoma, is grouped with them and is also aggressive. Which type someone has matters more than anything else for treatment and outlook. These tumors are uncommon, affecting roughly 3 in every million women each year. They are a type of uterine sarcoma, which is different from the much more common endometrial cancer that starts in the cells of the lining itself.

Causes & Risk Factors

In most people, no cause can be identified. Many of these tumors carry a specific genetic change in the tumor tissue, in which two genes break and fuse together. These changes help pathologists tell the types apart, but they do not explain why the tumor began. A few exposures are linked with a higher risk of uterine sarcomas in general. Radiation therapy to the pelvis in the past is an established risk, sometimes many years later. Long-term use (five years or more) of combined estrogen and progestin hormone therapy after menopause has been associated with a higher risk, while shorter use has not. Tamoxifen, a breast cancer medicine, is linked mainly with other uterine sarcoma types, and the absolute risk is low. Most people with these exposures never develop a sarcoma, and most people with a sarcoma had none of them. Low-grade tumors usually carry receptors for estrogen and progesterone, which means these hormones can fuel their growth. That is why hormones feature so prominently in treatment and follow-up.

How It's Diagnosed

Evaluation usually starts with a pelvic exam and an ultrasound. Magnetic resonance imaging (MRI) is the most useful scan for looking closely at a mass in the uterine wall, and certain features can raise suspicion of a sarcoma. Still, no scan can reliably tell an endometrial stromal tumor from a fibroid, the common noncancerous growth of the uterine muscle, so many of these tumors are discovered only after surgery for what seemed to be a fibroid. When the tumor reaches the uterine lining, a tissue sample taken by endometrial biopsy or by dilation and curettage (D and C, a procedure that gently scrapes tissue from the lining) can often find it. A tumor that sits entirely inside the muscle wall can be missed this way. The final diagnosis comes from a pathologist examining the tumor under a microscope, often with tests for hormone receptors and the gene changes typical of each type. Telling a benign nodule from a low-grade sarcoma depends on seeing whether the tumor's edge invades the surrounding muscle, so the whole tumor usually has to be removed and examined intact. Scans of the chest, abdomen and pelvis then help determine the stage: stage I is limited to the uterus, stage II has spread within the pelvis, stage III involves the abdomen or lymph nodes, and stage IV reaches the bladder or rectum or distant organs such as the lungs.

Treatment Options

Surgery is the main treatment for every type. It usually means a total hysterectomy (removal of the uterus and cervix) together with removal of both ovaries and fallopian tubes. The uterus should be removed in one piece. Cutting a tumor into fragments inside the abdomen, called morcellation, can spread sarcoma cells and worsen the outlook, so surgeons avoid it when a uterine mass has warning features, such as a fibroid that is new or growing quickly around or after menopause. Removing lymph nodes is not routine for low-grade disease but may be recommended for high-grade disease. For a benign nodule, hysterectomy is usually curative. For low-grade sarcoma, the ovaries are typically removed because they make estrogen, and keeping them is linked with a higher chance of the cancer returning. In carefully selected younger patients with very early disease, keeping the ovaries or even the uterus may be discussed, with the understanding that relapse is more likely and close monitoring is required. Fertility-sparing treatment is not considered for high-grade tumors. When low-grade sarcoma has spread or comes back, hormone therapy is the first choice. Aromatase inhibitors such as letrozole (Femara), pills used for breast cancer that sharply lower the body's estrogen, are preferred because they are generally well tolerated; progestins, medicines that act like the hormone progesterone, are an alternative. These can control the disease for long periods. Aromatase inhibitors can thin the bones, so bone health may be monitored. Further surgery to remove recurrent tumor is often combined with hormone therapy. Chemotherapy has little proven value in low-grade disease, and radiation is generally reserved for selected recurrences. High-grade sarcoma and undifferentiated uterine sarcoma do not respond to hormone therapy. After surgery, treatment for advanced disease usually involves chemotherapy, and radiation may be considered to lower the chance of the tumor returning in the pelvis. Because these tumors are rare and hard to treat, clinical trials are an important option.

What to Expect

The outlook depends mostly on the type and stage. A benign nodule removed by hysterectomy needs no further cancer treatment. Low-grade sarcoma is usually found while still limited to the pelvis, and about 80 to 100 percent of people are alive five years after diagnosis. High-grade sarcoma and undifferentiated uterine sarcoma are more serious: most are found at an advanced stage, and in reported series about one in three people with high-grade disease are alive at five years. Individual outcomes vary with stage and response to treatment. Low-grade sarcoma is known for coming back late, sometimes more than a decade after treatment, in the pelvis, abdomen or lungs. A recurrence is often still treatable with surgery and hormone therapy. For this reason, follow-up continues for many years: commonly every 3 months in the first year, every 6 months through year five, and yearly after that. Visits focus on symptoms and a physical exam, with scans used when something needs a closer look. Removing both ovaries before menopause brings on menopause right away, with symptoms such as hot flashes. Because estrogen exposure has been linked with a worse outcome in these hormone-sensitive tumors, any estrogen-containing hormone therapy should be decided together with the oncology team rather than started routinely.

When to Seek Help

Arrange an evaluation for vaginal bleeding after menopause, periods that become much heavier or irregular, or pelvic pain or pressure that does not go away. Tell your clinician if a known fibroid grows quickly around or after menopause, and ask about the possibility of sarcoma before any fibroid surgery that might involve morcellation. After treatment, contact your care team promptly about new vaginal bleeding, new pelvic or abdominal pain or swelling, or other new symptoms that persist, rather than waiting for the next scheduled visit, since late recurrences can occur.

Questions to Ask Your Doctor

  1. 1.Which type of endometrial stromal tumor do I have, and has the diagnosis been reviewed by a pathologist experienced with uterine sarcomas?
  2. 2.What stage is it, and what does that mean for my treatment options?
  3. 3.Do my ovaries need to be removed, and how would we manage the menopause symptoms that follow?
  4. 4.Is hormone therapy, chemotherapy or a clinical trial appropriate for my type of tumor?
  5. 5.What will my follow-up schedule look like, and for how many years?

Last reviewed • Oct 2026

Educational content, not medical advice.